Axsome Therapeutics

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axsome Therapeutics reports robust Q4 performance and eyes global expansion

Axsome Therapeutics had a strong Q4 2022, driven by successful commercialization of Auvelity and Sunosi.
While facing challenges such as legal disputes and payer coverage, the company is well-positioned for growth.
Strategic opportunities in expanding product portfolio and market access present avenues for future success.
Financially stable with a focus on innovation, Axsome is poised for continued growth and market expansion.

Axsome Therapeutics excels in Q1 2023 despite financial hurdles

Axsome Therapeutics demonstrated strong commercial and pipeline progress in Q1 2023, despite financial challenges.
The company's focus on expanding market share and optimizing commercial operations bodes well for future growth.
While facing challenges in sales guidance and NDA filings, Axsome's strong financial position and product performance offer opportunities for sustained success.

Axsome Therapeutics reports robust Q2 sales and expands product portfolio

Axsome Therapeutics demonstrated strong sales performance driven by Auvelity and Sunosi, with a focus on future growth potential.
Despite challenges such as increased costs and a net loss, the company is strategically expanding its product portfolio and market reach.
Opportunities lie in new FDA indications for existing products and the goal to have five marketed products by 2025.

Axsome Therapeutics reports robust Q3 earnings and outlines growth strategies

Axsome Therapeutics delivered strong revenue growth in Q3 2023, driven by Auvelity and Sunosi, showcasing a promising commercial outlook.
The company's pipeline progress and upcoming milestones reflect a commitment to innovation and expansion in the CNS therapeutic space.
While challenges like ongoing losses and strategic resource allocation persist, opportunities in new markets and product diversification offer avenues for future growth.

Axsome Therapeutics reports robust 2023 performance and eyes growth opportunities

Axsome Therapeutics had a strong financial performance in 2023, driven by the success of Auvelity and Sunosi. Despite challenges like increased expenses and net loss, opportunities for growth exist through new indications and expanded payer coverage.

Axsome Therapeutics excels in Q1 2024, poised for growth

Axsome Therapeutics demonstrated exceptional financial growth and pipeline advancements in Q1 2024, particularly in neuroscience programs like AXS-12.
Strong commercial performance of Auvelity and Sunosi, coupled with stable payer coverage and growth strategies, underpin the company's success trajectory.
While facing challenges related to study timelines and cybersecurity, Axsome Therapeutics remains poised to capitalize on upcoming milestones and market opportunities.

Axsome Therapeutics excels in Q2 2024, eyes market expansion

Axsome Therapeutics delivered a strong performance in Q2 2024, driven by revenue growth and progress on key product developments.
While facing challenges in market competition and operational execution, the company remains optimistic about future prospects.
Strategic opportunities in market expansion and product innovation position Axsome well for sustained growth and success in the CNS treatment space.

Axsome Therapeutics excels in Q3 with record revenue and pipeline progress

Axsome Therapeutics delivered a strong performance in Q3 2024, surpassing $100 million in quarterly product revenue and maintaining a solid financial position.
The company's strengths lie in its successful products, robust pipeline, and strategic commercial initiatives, supported by a strong cash reserve.
Challenges include managing expenses, navigating market dynamics, and sustaining commercial momentum, while opportunities exist in product launches and market expansion.
Overall, Axsome's performance reflects a balanced approach to growth, innovation, and market competitiveness, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

The stock price of Axsome Therapeutics Inc (NASDAQ: AXSM) increased over 5% pre-market today. This is why it happened.

AXSM Stock: Why It Increased Today

Groupon

Luminar Technologies

Las Vegas Sands

Workhorse Group

The Dow Jones dipped about 40 points, the S&P 500 was flat, and the Nasdaq saw some mild gains, led by Big Tech stocks such as Apple, Facebook, and Amazon. Find opportunities in today's market with the best short plays from Q.ai's deep learning algorithms.

Axsome Therapeutics Inc Ranked Among Today's Top Shorts After The European Central Bank Says It May Slow Down Bond Purchases

An unexpected regulatory setback weighed heavily on the biotech's shares last month.

Why Axsome Therapeutics Stock Cratered in August

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

Axsome (AXSM) Up 11.7% Since Last Earnings Report: Can It Continue?

Pulmonx

Vertex Pharmaceuticals

Stocks of biotech companies fighting COVID-19 have been great investments over the last two years. What stocks might zoom higher when the pandemic is over?

3 Healthcare Stocks That Might Skyrocket When COVID Is Over

COMPASS Pathways

Zogenix

All three stocks on this list can more than double your money according to investment bank analysts who cover them.

3 Biotech Stocks Wall Street Expects to Double Soon

There are still plenty of unknowns related to Axsome's FDA filing.

Buy, Sell, or Hold Axsome Therapeutics Stock After Its FDA Approval Delay?

The company still doesn't have much to say about the FDA and its experimental new anti-depression drug.

Here's Why Axsome Therapeutics Stock Is Surging Today

AstraZeneca

Nasdaq

Novavax

Pieris Pharma

Roche Holding AG

Cassava Sciences Inc

Seagen

Sanofi

Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?

Which Biotech Stock Will Shock the Market in 2022?

FDA delays decision on Axsome Therapeutics' (AXSM) new drug application for AXS-05, a potential treatment for major depressive disorder.

Axsome's (AXSM) Stock Up Despite FDA Delay on Depression Drug

Investors are happy that the FDA didn't ask for more information to supplement Axsome's regulatory filing for AXS-05.

Why Axsome Therapeutics Stock Is Jumping Today

Axsome Therapeutics Inc (NASDAQ: AXSM) stock is rising in premarket due to an update for its US marketing application seeking approval for AXS-05 for major depressive disorder (MDD). The FDA informed that it would not meet the target action date of August 22 for the application.

Why Is Axsome Therapeutics (AXSM) Stock Shooting Higher On Monday?

The shares of Axsome Therapeutics Inc (NASDAQ: AXSM) increased by over 20% pre-market. This is why it happened.

Axsome Therapeutics Shares Increase Over 20% Pre-Market: Why It Happened

NEW YORK, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) informed the Company in a teleconference on August 20, 2021, that its review of the new drug application (NDA) for AXS-05 for the treatment of major depressive disorder would not be completed by the Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2021. The FDA did not request additional information from the Company, and the review of the application is ongoing.

Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder

Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Axsome (AXSM) Stock?

Biogen

Here are three reasons why a buyout just might happen.

Could Biogen Acquire Axsome Therapeutics?

FibroGen

Boston Beer Company

Photo credit sergeitokmakov @ Pixabay Trading against the trend can be a very difficult way to generate returns in the market, yet there usually comes a time when a stock in a downtrend simply runs out of sellers.

3 Beaten Down Stocks that Could be Ready to Bounce

Iovance Biotherapeutics

These drugmakers delivered some upsetting news, but was it really so bad?

2 Beaten-Down Biotech Stocks: Are They Bargains Now?

Los Angeles, California--(Newsfile Corp. - August 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ: AXSM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Axsome disclosed on August 9, 2021, that the FDA had found...

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Axsome is down due to two adverse events. The first, rescinding of the BTD for AXS-12, is a non-event.

Axsome: Is The Pullback A Buying Opportunity?

The biotech stock has lost half of its value over the past week.

Why Shares of Axsome Therapeutics Are Down Friday

Los Angeles, California--(Newsfile Corp. - August 13, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ: AXSM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Axsome disclosed on August 9, 2021, that the FDA had found...

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ: AXSM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Axsome disclosed on August 9, 2021, that the FDA had found...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

The biotech stock is beaten down but still has potential catalysts ahead.

Is Axsome Therapeutics Stock Ready to Rebound?

NEW YORK--(BUSINESS WIRE)-- #AXSM--Scott+Scott Attorneys at Law LLP Announces Investigation into Axsome Therapeutics Inc. (AXSM)

News for Axsome Therapeutics Stock (AXSM)